首页> 外文期刊>The lancet oncology >Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial
【24h】

Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial

机译:I-III阶段乳腺癌中内部乳腺癌和内侧型淋巴结淋巴结辐照(EORTC 22922/10925):随机,第3阶段试验的15年结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background 10-year results from several studies showed improved disease-free survival and distant metastasis-free survival, reduced breast cancer-related mortality, and variable effects on overall survival with the addition of partial or comprehensive regional lymph node irradiation after surgery in patients with breast cancer. We present the scheduled 15-year analysis of the European Organisation for Research and Treatment of Cancer (EORTC) 22922/10925 trial, which aims to investigate the impact on overall survival of elective internal mammary and medial supraclavicular (IM-MS) irradiation.
机译:背景:几项研究的10年结果显示,乳腺癌患者术后局部或综合区域淋巴结放疗可提高无病生存率和无远处转移生存率,降低乳腺癌相关死亡率,并对总生存率产生可变影响。我们介绍了欧洲癌症研究与治疗组织(EORTC)22922/10925试验计划的15年分析,该试验旨在调查选择性内乳和锁骨上内侧(IM-MS)照射对总体生存率的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号